medigraphic.com
ISSN 0185-3325 (Impreso)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2001, Número 1

<< Anterior Siguiente >>

Salud Mental 2001; 24 (1)


Marcadores diagnósticos y mecanismos neuroquímicos de la encefalopatía secundaria a la insuficiencia hepática

Hernández-Ávila CA, Ortega-Soto HA

Idioma: Español
Referencias bibliográficas: 102
Paginas: 48-59
Archivo PDF: 162.95 Kb.


RESUMEN

La encefalopatía hepática (EH) es un trastorno neuropsiquiátrico complejo secundario a la insuficiencia hepática aguda o crónica, para el cual no se cuenta con marcadores diagnósticos específicos que contribuyan a dilucidar su mecanismo neuroquímico exacto. Como posibles mecanismos de este trastorno se han propuesto los efectos neurot óxicos de la acumulación del amonio, la producción de neurotransmisores falsos, y el incremento del tono inhibitorio GABAergico en el SNC. No obstante, las diversas investigaciones que han explorado estas hipótesis han arrojado hallazgos contradictorios. Diversos informes han propuesto que el incremento de las concentraciones de ligandos endógenos en el receptor de las benzodiacepinas (LRBZD) pudiera contribuir a la patogénesis de la EH. Sin embargo, los datos disponibles también sugieren que los síntomas neuropsiquiátricos de la EH difícilmente pueden explicarse únicamente por la acumulación de estos compuestos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. AL MARDINI H, BARTLETT K, RECORD CO: Blood and brain concentrations of mercaptans in hepatic and methanethiol induced coma. Gut, 25:284-290, 1984.

  2. BANSKY G, MEIER PJ, ZIEGLER WH: Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-7788). Lancet, 1:1324, 1985.

  3. BARALDI M, ZENEROLI ML, RICCI P, CASELGRANDI E, VENTURA E: Down regulation of striatal dopamine receptors in experimental hepatic encephalopathy. LifeSciences, 32(13): 1417-25, 1983.

  4. BARNARD EA, DARLISON MG, SEEBURG P: Molecular bioloy of the GABAA receptor: the receptor channel superfamily. Trends Neuroscience, 10:502–509, 1987.

  5. BASILE AS, GAMMAL SH, MULLEN KD, JONES EA,SKOLNICK P: Differential responsiveness of cerebellar Purkinje: neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. Neuroscience, 8:2414-2421, 1988.

  6. BASILE AS, HARRISON PM, HUGHES RD, GU ZQ,PANNELL L. MCKINNEY A. JONES EA. WILLIAMS R: Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology, 19:112-121, 1994.

  7. BASILE AS, HUGHES RD, HARRISON PM, MURATA Y, PANNELL L, JONES EA, WILLIAMS R. SKOLNICK P: Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.New England Medicine, 325:473-478, 1991.

  8. BASILE AS, PANNELL L, JAOUNI T, GAMMAL SH,FALES HM, JONES EA, SKOLNICK P: Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proceedings of the National Academy of Sciences of the United States of America, 87:5263-5267, 1990.

  9. BASSETT ML, MULLEN KD, SKOLNICK P, JONES EA: Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology, 93:1069-1077, 1987.

  10. BATES TE, WILLIAMS SR, KAUPPINEN RA, GADIAN DG: Observation of cerebral metabolites in an animal model of acute liver failure in vivo: a 1H and 31P nuclear magnetic resonance study. J Neurochemistry, 53:102-110, 1989.

  11. BESSMAN SP, BESSMAN AN: The cerebral and peripheral uptake of ammonia in liver disease with a hypothesis for the mechanism of hepatic coma. J Clinical Investigation, 34:622- 628, 1975.

  12. BURT DR, KAMATCHI GL: GABAA receptor subtypes: from pharmacology to molecular biology. FASEB J, 5:2916– 2923, 1991.

  13. BUTTERWORTH RF, LAVOI J, GIGUERE JF,POMIER-LAYRARGUES G: Affinities and densities of GABA-A receptors and of central benzodiazepine receptors are unchanged in autopsied brains tissue from cirrhotic patients with hepatic encephalopathy. Hepatology, 8:1084-1088, 1988.

  14. BUTTERWORTH RF: Neuroactive amino acids in hepatic encephalopathy. Metabolic Brain Disease,11:165-173, 1996.

  15. BUTTERWORTH RF, GIGUERE JF: Cerebral aminoacids in portal-systemic encephalopathy: lack of evidence for altered gamma-aminobutyric acid (GABA) function. Metabolic Brain Disease, 1:221-228, 1986.

  16. CADRANEL JF, EL YOUNSI M, PIDOUX B, ZYLBERBERG P, BENHAMOU Y, VALLA D, OPOLON P: Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. European J Gastroenterology Hepatology, 7:325- 329, 1995.

  17. CONN HO, LEEVY CM, VLAHCEVIC ZR,RODGERS JB, MADDREY WC, SEEFF L, LEVY LL: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology, 72:573-83, 1977.

  18. CONN HO, LIEBERTHAL MM: The Hepatic Coma Syndromes and Lactulosa. Williams & Wilkins, Baltimore, 1978.

  19. CROSSLEY IR, WARDLE EN, WILLIAMS R:Biochemical mechanisms of hepatic encephalopathy. Clinical Science, 64:247-252, 1983.

  20. DEUTZ NE, CHAMULEAU RA, DE GRAAF AA,BOVEE WM, DE BEER R: In vivo 31P NMR spectroscopy of the rat cerebral cortex during acute hepatic encephalopathy. NMR Biomedicine, 1:101-106, 1988.

  21. DUFFY TE, VERGARA F, PLUM F: Alpha-ketoglutaramate in hepatic encephalopathy. Research Publications - Association for Research in Nervous Mental Disease. 53: 39- 52, 1974.

  22. FERENCI P, JONES EA, HANBAUER I: Lack of evidence for impaired dopamine receptor function in experimental hepatic coma in the rabbit. Neuroscience Letters, 65:60-64, 1986.

  23. FERENCI P, SCHAFER DF, KLEINBERGER G,HOOFNAGLE JH, JONES EA: Serum levels of gammaaminobutyric- acid-like activity in acute and chronic hepatocellular disease. Lancet, 2:811-814, 1983.

  24. FERENCI P, GRIMM G, GANGL A: Successfull longtime treatment of chronic hepatic encephalopathy with a benzodiazepine antagonist. Hepatology, 7:1064, 1987.

  25. FERREIRA MR, GAMMAL SH, JONES EA: Resistance to 3-mercaptopropionic acid-induced seizures in hepatic encephalopathy. Hepato-Gastroenterology, 44:766-769, 1997.

  26. FISCHER JE, BALDESSARINI RJ: False neurotransmitters and hepatic failure. Lancet, 2:75-80, 1971.

  27. FLANNERY DB, HSIA YE, WOLF B: Current status of hyperammonemic syndromes. Hepatology, 2:495-506, 1982.

  28. FOWLER JM, SCHAFER DF: A mechanism for the increased sensitivity to benzodiazepines in hepatocellular failure: evidence from an animal model. Gastroenterology, 80:1359, 1981.

  29. GABUZDA D, PHILIPS GB, DAVIDSON CS: Reversible toxic manifestations in patients with cirrhosis of the liver given cationic-exchange resins. New England J Medicine, 246:124–130, 1952.

  30. GAMMAL SH, BASILE AS, GELLER D, SKOLNIK P, JONES EA: Reversal of the behavioural and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology, 11:371-378. 1990.

  31. GELGER A, MAGNES J, TAYLOR RM: Effect of blood constituents on uptake of glucose and on metabolic rate of the brain in perfusion experiments. American J Physiology, 177:138-149, 1954.

  32. GOODAY R, HAYES PC, BZEIZI K, O’CARROLL RE: Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. Psychopharmacology, 119:295-298, 1995.

  33. GREGORIOS JB, MOZES LW, NORENBERG MD: Morphologic effects of ammonia on primary astrocyte cultures. II. Electron microscopic studies. J Neuropathology Experimental Neurology, 44:404-414, 1985.

  34. GRIMM G, LENZ K, KLEINBERGER G: Ro 15-1788 improves coma in 4 out of 5 patients with fulminant hepatic failure: verification by long latency auditory and somatosensory evoked potentials. J Hepatology, 4:521, 1987.

  35. HAHN M, MASSEN O, NENCKI M, PAVLOV J: Die ecksche fistel zwischen der unteren hohlvene und der pfortader und ihre folgen für den organismus. Arch Exp Path Pharmakol, 32:161–170, 1893.

  36. HAMMOND EJ, WILDER BJ: Gamma-vinyl GABA: a new antiepileptic drug. Clinical Neuropharmacology, 8:1-12, 1985.

  37. HERNANDEZ-AVILA CA, SHOEMAKER WJ, ORTEGA-SOTO HA: Plasma concentrations of endogenous benzodiazepine-receptor ligands in patients with hepatic encephalopathy: a comparative study. J Psychiatry Neuroscience, 23:217-222, 1998.

  38. HINDFELT B, PLUM F, DUFFY TE: Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts.J Clinical Investigation, 59:386-396, 1977.

  39. HOROWITZ ME, SCHAFER DF, MOLNAR P,JONES EA, BLASBERG RG, PATLAK CS, WAGGONER J, FENSTERMACHER JD: Increased blood-brain transfer in a rabbit model of acute liver failure. Gastroenterology, 84:1003-1011, 1983.

  40. ILES JF, JACK JJ: Ammonia: assessment of its action on postsynaptic inhibition as a cause of convulsions. Brain, 103:555-578, 1980.

  41. JONES DB, MULLEN KD, ROESSLE M, MAYNARD T, JONES EA: Hepatic encephalopathy. Application of visual evoked responses to test hypotheses of its pathogenesis in rats. J Hepatology, 4:118-126, 1987.

  42. JONES EA, SKOLNICK P, GAMMAL SH, BASILE AS, MULLEN KD: NIH conference. The gamma-aminobutyric acid A (GABAA) receptor complex and hepatic encephalopathy. Some recent advances. Annals Internal Medicine, 110:532-46, 1989.

  43. LAVIZZARI GS, STEINMAN E: Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet, 1:1324-1325, 1985.

  44. LAVOIE J, BUTTERWORTH RF: Peripheral-type (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. Alcohol Alcoholism (Supl), 2:181-185, 1993.

  45. LEONG DK, THERRIEN G, SWAIN MS, BUTTERWORTH RF: Densities of binding sites for the “peripheraltype ” benzodiazepine receptor ligand 3H-PK11195 are increased in brain 24-hours following portacaval anastomosis. Metabolic Brain Disease , 9: 267-273, 1994.

  46. LEVY LJ, BOLTON RP, LOSOWSKY MS: The use of the visual evoked potential (VEP) in delineating a state of subclinical encephalopathy. A comparison with the number connection test (NCT). J Hepatology, 5:211-217, 1987.

  47. LEVY LJ, LOSOWSKY MS: Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease. Hepato-Gastroenterology, 36:494-498, 1989.

  48. LOCKWOOD AH, MCDONALD JM, REIMAN RE,GELBARD AS, LAUGHLIN JS, DUFFY TE, PLUM F: The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clinical Investigation, 63:449-460, 1979.

  49. LUDDENS H, WISDEN W: Function and pharmacology of multiple GABAA receptor subunits. Trends Pharmacological Sciences, 12:49-51, 1991.

  50. MADDISON JE, WATSON WE, JOHNSTON GA: L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. Metabolic Brain Disease, 10:135-141, 1995.

  51. MICHALAK A, BUTTERWORTH J, BUTTERWORTH RF: Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology, 24:908-913, 1996.

  52. MICHEL H, SOLERE M, GRANIER P, CAUVET G, BALI JP, PONS F, BELLET-HERMANN H: Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial. Gastroenterology, 79:207-211, 1980.

  53. MORONI F, LOMBARDI G, CARLA V, LAL S, ETIENNE P, NAIR NP: Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. J Neurochemistry, 47:1667-1671, 1986.

  54. MULLEN KD, BASILE AS: Benzodiazepine-receptor antagonists and hepatic encephalopathy: Where do we stand? Gastroenterology, 105:937-940, 1993.

  55. OLASMAA M, ROTHESTEIN JD, GOLDMAN M: Endogenous benzodiazepines in hepatic encephalopathy. Lancet, 1:491-492, 1989.

  56. OLASMAA M, ROTHSTEIN JD, GUIDOTTI A,WEBER RJ, PAUL SM, SPECTOR S, ZENEROLI ML, BARALDI M, COSTA E: Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochemistry, 55:2015-2023, 1990.

  57. OLSEN RW, TOBIN AJ: Molecular biology of GABAA receptors. FASEB J, 4:1469–1480, 1990.

  58. PAPPAS SC, FERENCI P, SCHAFER DF, JONES EA: Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and coma induced by synergistic neurotoxins. Gastroenterology, 86:546-851, 1984.

  59. POMIER-LAYRARGUES G, GIGUERE JF, LAVOIE J, WILLIAMS B, BUTTERWORTH RF: Pharmacokinetics of benzodiazepine antagonist Ro15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology, 10:969–972, 1989.

  60. POMIER-LAYRARGUES G, NGUYEN NH, FAUCHER C, GIGUERE JF, BUTTERWORTH RF: Subclinical hepatic encephalopathy in cirrhotic patients: Prevalence and relationship to liver function. Canadian J Gastroenterolgy, 5:121–125, 1991.

  61. POMIER-LAYRARGUES G, GIGUERE JF, LAVOIE J, PERNEY P, GAGNON S, D’AMOUR M, WELLS J, BUTTERWORTH RF: Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology, 19:32-37, 1994.

  62. PRITCHETT DB, SONTHEIMER H, SHIVERS BD,YMER S, KETTENMANN H, SCHOFIELD PR, SEEBURG PH: Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature, 338:582- 585, 1989.

  63. RAABE W: The H-reflex in the encephalopathy due to ammonia intoxication. Experimental Neurology, 96:601-611, 1987.

  64. RAO VL, MURTHY CR, BUTTERWORTH RF:Glutamatergic synaptic dysfunction in hyperammonemic syndromes. Metabolic Brain Disease, 7:1-20, 1992.

  65. ROCHE-SICOT J, SICOT C, PEIGNOUX M, BOURDIAU D, DEGOS F, DEGOS JD, PRANDI D,RUEFF B, BENHAMOU JP: Acute hepatic encephalopathyin the rat: the effect of cross-circulation. ClinicalScience Molecular Medicine, 47:609-615, 1974.

  66. ROSSLE M, DECKERT J, JONES EA: Autoradiographic analysis of GABA- benzodiazepine receptors in ananimal model of acute hepatic encephalopathy. Hepatology,10:143-47, 1989.

  67. ROTHSTEIN JD: Benzodiazepine-receptor ligands and hepatic encephalopathy: a causal relationship? Hepatology,19:248-250, 1994.

  68. ROTHSTEIN JD, MCKHANN G, GUARNERI P,BARBACCIA ML, GUIDOTTI A, COSTA E: Cerebrospinalfluid content of diazepam binding inhibitor inchronic hepatic encephalopathy. Annals Neurology, 26:57-62, 1989.

  69. ROY S, POMIER-LAYARGUES G, BUTTERWORTH RF, HUET PM: Hepatic encephalopathy incirrhotic and portocaval shunted dogs: Lack of changes inbrain GABA uptake, brain GABA levels and brain glutamicacid decarboxylase activity and brain postsynaptic GABAreceptors. Hepatology, 8:845-849, 1988.

  70. SAMSON Y, BERNUAU J, PAPPATA S, CHAVOIX C, BARON JC, MAZIERE MA: Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy. New England J Medicine, 316:414-415, 1987.

  71. SANDFORD NL, SAUL RE: Assessment of hepatic encephalopathy with visual evoked potentials compared with conventional methods. Hepatology, 8:1094–1098, 1988.

  72. SCHAFER DF, THAKUR AK, JONES EA: Acute hepatic coma and inhibitory neurotrasmission: increse in gama-amino-butyric acid levels in plasma and receptors in brain. Gastroenterology, 79:1123, 1980.

  73. SCHAFER DF, FOWLER JM, JONES EA: Colonic bacteria: a source of gamma-aminobutyric acid in blood. Proceedings Society Experimental Biology Medicine, 167:301-303, 1981.

  74. SCHAFER DF, FOWLER JM, MUNSON PJ,THAKUR AK, WAGGONER JG. JONES EA: Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Laboratory Clinical Medicine, 102:870-880, 1983.

  75. SCHAFER DF, PAPPAS SC, BRODY LE, JACOBS R, JONES EA: Visual evoked potentials in a rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with drug-induced comas. Gastroenterology, 86:540-545, 1984.

  76. SCHAFER DF, WAGGONER JG, JONES EA: Sera from rabbits in acute hepatic coma inhibit the binding of gama-amino-butiric acid. Gastroenterology, 78:1320, 1980.

  77. SEDA HW, HUGHES RD, GOVE CD, WILLIAMS R: Inhibition of rat brain Na+K+-ATPase activity by serum from patients with fulminant hepatic failure. Hepatology, 4:74-79, 1984.

  78. SMIALOWSKI A: The effect of intrahippocampal administration of gama-amino-butiric acid (GABA). En: Fonum F (ed.). Amino Acids as Chemical Trasmitters. Plenum Press, Nueva York, 1978:1977-1980.

  79. SOURKES TL: Tryptophan in hepatic coma. J Neural Transmission (Supl). 14:79-86, 1978.

  80. STEINDL P, PUSPOK A, DRUML W, FERENCI P: Beneficial effects of pharmacological modulation of the GABA - benzodiazepine receptor on hepatic encephalopathy in the rat: Comparison with uremic encephalopathy. Hepatology, 14:963–968, 1991.

  81. TALLMAN J, THOMAS J, GALLAGER D: GABAergic modulation of benzodiazepine binding site sensitivity. Nature, 274:384-385, 1978.

  82. THOMPSON JS, SCHAFER DF, SCHAFER GJ,HODGSON PE: Gamma-aminobutyric acid plasma levels and brain binding in Eck fistula dogs. J Surgical Research, 38:143-148, 1985.

  83. TRAN VT, SNYDER SH, MAJOR LF, HAWLEY RJ: GABA receptors are increased in brains of alcoholics. Annals Neurology, 9:289-292, 1981.

  84. TREWBY PN, CASEMORE C, WILLIAMS R: Continuous bipolar recording of the EEG in patients with fulminant hepatic failure. Electroencephalography Clinical Neurophysiology, 45:107-110, 1978.

  85. URIBE M, FARCA A, MARQUEZ MA, GARCIARAMOS G, GUEVARA L: Treatment of chronic portal systemic encephalopathy with bromocriptine: a doubleblind controlled trial. Gastroenterology, 76:1347-1351, 1979.

  86. URIBE M, GARCIA-RAMOS G, RAMOS M, VALVERDE C, MARQUEZ MA, FARCA A, GUEVARA L: Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. American J Gastroenterology,78:517-22, 1983.

  87. VAN DER RIJT CC, SCHALM SW, MEULSTEE J,STIJNEN T: Flumazenil therapy for hepatic encephalopathy: A double-blind cross-over study (Abstract). Hepatology, 10:590, 1989.

  88. VAN DER RIJT CC, SCHALM SW, MEULSTEE J,STIJNEN T: Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study. Gastroenterologie Clinique et Biologique, 19:572-580, 1995.

  89. VERGARA F, PLUM F, DUFFY TE: Alpha-ketoglutaramate:increased concentrations in the cerebrospinal fluid of patients in hepatic coma. Science, 183:81-83, 1974.

  90. WINDUS-PODEHL G, LYFTOGT C, ZIEVE L,BRUNNER G: Encephalopathic effect of phenol in rats. J Laboratory Clinical Medicine, 101:586-592, 1983.

  91. WOODGATE C, SCOTT DF: Triphasic waves with particular emphasis on phase shift. Electroencephalogr Clin Neurophysiol, 55:39 P, 1983.

  92. YANG SS, CHU NS, LIAW YF: Somatosensory evoked potentials in hepatic encephalopathy. Gastroenterology, 89:625- 630, 1985.

  93. YURDAYDIN C, WALSH TJ, ENGLER HD, HA JH, LI Y, JONES EA, BASILE AS: Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Research, 679:42-8, 1995.

  94. ZENEROLI ML, PINELLI G, GOLLINI G, PENNE A, MESSORI E, ZANI G, VENTURA E: Visual evoked potential: a diagnostic tool for the assessment of hepatic encephalopathy. Gut, 25:291-299, 1984.

  95. ZENEROLI ML, VENTURA E, BARALDI M,PENNE A, MESSORI E, ZIEVE L: Visual evoked potentials in encephalopathy induced by galactosamine, ammonia, dimethyldisulfide, and octanoic acid. Hepatology, 2:532-538, 1982.

  96. ZENEROLI ML, VENTURINI I, STEFANELLI S,FARINA F, MIGLIOLI RC, MINELLI E, AMEDEI ER, FERRIERI A, AVALLONE R, BARALDI M: Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacological Research, 35:557-560, 1997.

  97. ZIEVE L, DOIZAKI WM, LYFTOGT C: Brain methanethiol and ammonia concentrations in experimental hepatic coma and coma induced by injections of various combinations of these substances. J Laboratory Clinical Medicine, 104:655-664, 1984.

  98. ZIEVE L, FERENCI P, RZEPCZYNSKI D, EBNER J, ZIMMERMANN C: A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neural gamma-aminobutyric acid (GABA) binding. Metabolic Brain Disease, 2:201-205, 1987.

  99. ZIEVE L: Hepatic encephalopathy. En: Schiff L, Schiff ER (eds). Diseases of the Liver. JB Lippincott, Filadelfia, 1987, 925-948.

  100. ZIEVE L, OLSEN RL: Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine? Gut, 18:688- 691, 1977.

  101. ZIEVE L: The mechanism of hepatic coma. Hepatology, 1:360-365, 1981.

  102. ZORUMSKY FC, ISENBERG EK: Insights into the structure and function of GABA-Benzodiazepine receptors: Ion chanels and psychiatry. American J Psychiatry, 148:162-173, 1991.




2020     |     www.medigraphic.com